Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127905 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL29508172 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL5084837 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL5204684 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL16884634 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL291932 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL835295 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL2825440 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL2825437 | 1.00 | MAPT (0.55) | MAPTEPHX2CNR2KDM4EALDH1A1 | |
| SCHEMBL21376096 | 0.91 | MAPT (0.64) | MAPTEPHX2CNR2ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119672974-A | Cross intersection induction type full-red time calculation method and processor | 安徽建筑大学 | 2025-03-21 | — | — | CN | claimed |
| EP-4128509-B1 | DC-TO-DC CONVERTER WITH FREEWHEELING CIRCUITS | HUAWEI TECH CO LTD (CN) | 2024-09-18 | — | — | EP | claimed |
| CN-115001957-B | System and method for rapidly and automatically upgrading software | 苏州思萃工业互联网技术研究所有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20230414628-A1 | METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 | RAMESH SANATH KUMAR (US) | 2023-12-28 | — | — | US | claimed |
| EP-4128509-A1 | DC-TO-DC CONVERTER WITH FREEWHEELING CIRCUITS | Huawei Technologies Co., Ltd. (CN) | 2023-02-08 | — | — | EP | claimed |
| WO-2023275796-A1 | HETEROCYCLIC DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE 3 INHIBITORS | NOVARTIS AG (CH) | 2023-01-05 | — | — | WO | claimed |
| EP-4098256-A1 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST | Novartis AG (CH) | 2022-12-07 | — | — | EP | claimed |
| US-20220169693-A1 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2022-06-02 | — | — | US | claimed |
| CN-122094935-A | Amide prodrugs and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122055144-A | Compounds and methods for treating cancer | 维瓦斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4737478-A1 | MODIFIED G PROTEIN COUPLED RECEPTOR AND USE THEREOF | Alphelix Biotech Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12612401-B2 | Crystalline forms of an S1P receptor modulator | Oppilan Pharma Limited (GB) | 2026-04-28 | — | — | US | disclosed |
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | NOVARTIS PHARMA AG (CH) | 2026-04-23 | — | — | US | disclosed |
| US-20080249160-A1 | Nematicidal Fatty Acid and Fatty Acid Ester Related Compounds | DIVERGENCE, INC. | 2008-10-09 | — | — | US | disclosed |
| CN-1649578-A | Nematicidal fatty acid and fatty acid ester related compounds | DIVERGENCE INC (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005023989-A2 | NEMATICIDAL FATTY ACID AND FATTY ACID ESTER RELATED COMPOUNDS | DIVERGENCE, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1480633-A2 | NEMATICIDAL FATTY ACID AND FATTY ACID ESTER RELATED COMPOUNDS | Divergence, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040157803-A1 | Nematicidal fatty acid and fatty acid ester related compounds | DIVERGENCE, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2003075656-A2 | NEMATICIDAL FATTY ACID AND FATTY ACID ESTER RELATED COMPOUNDS | DIVERGENCE, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | PMP22, PSMB2, SMN1; SMN2 | MAPT 1937/4885EPHX2 3678/4885CNR2 770/4885 |
| US-20080249160-A1 | Nematicidal Fatty Acid and Fatty Acid Ester Related Compounds | FASN, ELOVL3, ALOX5 | MAPT 4144/4885EPHX2 215/4885CNR2 320/4885 |
| US-20220169693-A1 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | AGER, IGSF11, ICAM1 | MAPT 2858/4885EPHX2 2139/4885CNR2 2195/4885 |
| US-12612401-B2 | Crystalline forms of an S1P receptor modulator | S1PR2, S1PR1, S1PR5 | MAPT 1155/4885EPHX2 1179/4885CNR2 8/4885 |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | MAPT 263/4885EPHX2 113/4885CNR2 6/4885 |
| US-20040157803-A1 | Nematicidal fatty acid and fatty acid ester related compounds | FASN, ELOVL3, ALOX5 | MAPT 4144/4885EPHX2 215/4885CNR2 320/4885 |
| US-20230414628-A1 | METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 | GPX4, GPX1, MPO | MAPT 3351/4885EPHX2 871/4885CNR2 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.